Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors

Trial Profile

A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prexasertib (Primary) ; Samotolisib (Primary) ; Cetuximab; Cisplatin; Fluorouracil; Folinic acid; Granulocyte colony-stimulating factors; Pemetrexed
  • Indications Advanced breast cancer; Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 04 Jun 2019 Results (n=50) assessing escalating doses of prexasertib and LY3023414 presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 15 May 2019 According to a Eli Lilly media release, data from this trial will be presented at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019.
    • 05 Feb 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top